93106-59-3

中文名称盐酸恩诺沙星

英文名称 ENROFLOXAIN HYDROCHLORIDE

CAS 93106-59-3

分子式 C19H23ClFN3O3

分子量 395.856

MOL 文件 93106-59-3.mol

更新日期 2023/10/30 13:34:02

93106-59-3 结构式

基本信息物理化学性质安全数据盐酸恩诺沙星价格(试剂级) 常见问题列表

基本信息

中文别名

恩诺沙星单盐酸盐

英文别名

ENROFLOXAIN HYDROCHLORIDE
3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI)

所属类别

医药中间体：原料药中间体

物理化学性质

储存条件-20°C储存

溶解度H₂O: 2 mg/mL, clear (Warmed)

形态Solid

颜色White to off-white

水溶解性Water : 7.14 mg/mL (Need ultrasonic)

InChIInChI=1S/C19H22FN3O3.ClH/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12;/h9-12H,2-8H2,1H3,(H,25,26);1H

InChIKeyPZJWYUDBXNNVLZ-UHFFFAOYSA-N

SMILESN1(C2CC2)C2=C(C=C(F)C(N3CCN(CC)CC3)=C2)C(=O)C(C(O)=O)=C1.[H]Cl

安全数据

危险性符号(GHS) 健康危害 (GHS08)

GHS08,GHS07

警示词危险

危险性描述H302,H317,H334

防范说明P261-P264-P272-P280-P301+P312-P302+P352

盐酸恩诺沙星价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2026/06/05	HY-B0502AR	盐酸恩诺沙星 Enrofloxacin monohydrochloride (Standard)	93106-59-3	10 mg	340元
2026/06/05	HY-B0502AR	盐酸恩诺沙星 Enrofloxacin monohydrochloride (Standard)	93106-59-3	25 mg	660元
2026/06/05	HY-B0502AR	盐酸恩诺沙星 Enrofloxacin monohydrochloride (Standard)	93106-59-3	50 mg	1000元

常见问题列表

生物活性

Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) 是一种有效的抗生素，作用于 Mycoplasma bovis，MIC90 为 0.312 μg/ mL。

靶点

MIC90: 0.312 μg/mL ( Mycoplasma bovis )

体外研究

Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL.

体内研究

Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment.